Cat.No. : CSC-SC005718 Host Cell: HEK293 (CHO and other cell types are also available)
| Cat. No. | CSC-SC005718 |
| Description | Using Creative Biogene's proprietary lentiviral vectors, we subclone the target gene into lentivector, generate the lentivirus particles, sequentially infect the cell line HEK293 (other cell types are also available according to your requirements), and select the clones constantly expressing target gene at high level. |
| Gene | FGFR1 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | HEK293 (CHO and other cell types are also available) |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Signaling pathway research 3. Drug screening and toxicology 4. Disease research |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Size Form | 2 × 10^6 cells / vial |
| Shipping | Dry Ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Gene Name | FGFR1 fibroblast growth factor receptor 1 [ Homo sapiens ] |
| Gene Symbol | FGFR1 |
| Synonyms | CEK; FLG; HH2; OGD; FLT2; KAL2; BFGFR; CD331; FGFBR; FLT-2; HBGFR; N-SAM; FGFR-1; bFGF-R-1 |
| Gene Description | fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) |
| Gene ID | 2260 |
| UniProt ID | P11362 |
| mRNA Refseq | NM_023106.2 |
| Protein Refseq | NP_075594.1 |
| Chromosome Location | 8p12 |
| Function | ATP binding; cell adhesion molecule binding; fibroblast growth factor binding; fibroblast growth factor-activated receptor activity; fibroblast growth factor-activated receptor activity; glycoprotein binding; heparin binding; identical protein binding; protein binding; protein homodimerization activity; protein tyrosine kinase activity; |
| Pathway | Adaptive Immune System, organism-specific biosystem; Adherens junction, organism-specific biosystem; Adherens junction, conserved biosystem; Axon guidance, organism-specific biosystem; Constitutive PI3K/AKT Signaling in Cancer, organism-specific biosystem; DAP12 interactions, organism-specific biosystem; DAP12 signaling, organism-specific biosystem; |
| MIM | 136350 |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Hepatocellular carcinoma (HCC) is a highly aggressive solid tumor with limited treatment options. Lenvatinib is currently the second approved first-line drug for the treatment of advanced HCC, but cases of lenvatinib resistance have been reported clinically. Overexpression of fibroblast growth factor receptor 1 (FGFR1) is closely associated with advanced HCC. Here, researchers found that FGFR1 overexpression and activation of its downstream AKT/mTOR and ERK signaling pathways can induce lenvatinib resistance in HCC cells. In vivo and in vitro experimental results showed that Oxysophocarpine can inhibit the proliferation of FGFR1-overexpressing HCC cells and induce their apoptosis. Oxysophocarpine can further enhance the sensitivity of FGFR1-overexpressing HCC cells to lenvatinib. Mechanistic studies showed that Oxysophocarpine enhances the sensitivity of FGFR1-overexpressing HCC cells to lenvatinib by downregulating FGFR1 expression and downstream AKT/mTOR and ERK signaling pathways. These data collectively suggest that FGFR1 overexpression may be a potential cause of lenvatinib resistance, and that Oxysophocarpine may be an ideal drug to be used in combination with lenvatinib for the treatment of HCC.
To investigate whether Oxysophocarpine could rescue the sensitivity of FGFR1-overexpressing hepatocellular carcinoma cells to lenvatinib, researchers treated FGFR1-overexpressing Hep3B and HepG2 cells with 10 μM Oxysophocarpine in combination with 5 μM lenvatinib. In cell proliferation assays, Oxysophocarpine combined with lenvatinib exerted the most suppressive influence on the cell proliferation compare to control or alone treatment (Figure 1A). In colony formation assays, the combination significantly inhibited colony formation in FGFR1-overexpressing Hep3B and HepG2 cells compared to either Oxysophocarpine or lenvatinib alone (Figure 1B and C). They also investigated the effect of the combination on the migration of FGFR1-overexpressing hepatocellular carcinoma cells. FGFR1-overexpressed Hep3B and HepG2 cells were previously treated with 10 μM Oxysophocarpine combined with 5 μM lenvatinib for 24 h. Oxysophocarpine combined with lenvatinib evidently inhibited the migration of FGFR1-overexpressed Hep3B and HepG2 cells (Figure 1D and E). In summary, the researchers hypothesize that Oxysophocarpine enhances the sensitivity of FGFR1-overexpressing Hep3B and HepG2 cells to lenvatinib in vitro.
Figure 1. Oxysophocarpine sensitized FGFR1-overexpressed Hep3B and HepG2 cells to lenvatinib in vitro. (Zhao Z, et al., 2021)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
